{'fraction_non_alphanumeric': 0.021922428330522766, 'fraction_numerical': 0.0, 'mean_word_length': 5.6, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Update and perspectives of anabolic therapies for osteoporosis].

Daily subcutaneous self-injection and weekly subcutaneous injection formulas of teriparatide are available as anabolic agents in Japan. These injection formulas are expected to serve as a new treatment choice for high fracture-risk patients with osteoporosis. In addition, studies using new anabolic agents such as PTHrP, calcilytics, and Wnt inhibitor antagonists/antibodies are under way to develop new anabolic agents. These agents may become new treatment drugs for osteoporotic patients especially with low bone turnover.